On this basis, we designed a biologically active YTHDF3-derived peptide to competitively inhibit YTHDF3 palmitoylation mediated by ZDHHC20, which in turn downregulated MYC expression and inhibited the progression of KRAS mutant pancreatic cancer (schematic in Fig. 10). This evidence concerns the gene MYC and pancreatic neoplasm.